Similarly, the HER2xSORT1 ADC promoted more marked TGI in HER2-low BC cell line xenografts (two weekly 10 mg/kg doses) compared with T-DXd and monospecific parental ADCs [213]. Here, ERBB2 is linked to breast cancer.